Loading...
Back to narrative

VMD: Share Repurchases Will Support Stronger Per-Share Upside Potential

US Aging And Telehealth Will Expand Home Care

VMD logo
VMD
AnalystHighTarget
Not Invested
Published 18 May 2025

Update shared on 12 Dec 2025

n/a
n/a
AnalystHighTarget's Fair Value
n/a
Loading
1Y
-5.2%
7D
0.7%

Analysts have modestly increased their price target on Viemed Healthcare to approximately $15.00 per share, up from about $15.00. They cite slightly stronger expectations for revenue growth and profit margins, along with a lower future price-to-earnings multiple that together support a more favorable risk-return profile.

What's in the News

  • Lowered full year 2025 net revenue guidance to a range of $271 million to $273 million, narrowing from the prior $271 million to $277 million outlook (company guidance)
  • Completed a share repurchase program announced June 9, 2025, buying back 1,976,441 shares, or 4.99% of outstanding shares, for a total of $13.23 million (company filing)
  • Repurchased 1,706,380 shares, or 4.31% of outstanding shares, for $11.4 million between July 1, 2025 and September 23, 2025 under the same buyback authorization (company filing)

Valuation Changes

  • Fair Value Estimate remained effectively unchanged at approximately $15.00 per share.
  • Discount Rate increased slightly from about 6.78 percent to roughly 6.96 percent, implying a modestly higher required return.
  • Revenue Growth assumptions rose moderately from around 18.9 percent to about 20.7 percent, reflecting stronger topline expectations.
  • Net Profit Margin forecast improved slightly from approximately 7.0 percent to about 7.5 percent, indicating a modest upgrade to profitability.
  • Future P/E multiple decreased significantly from roughly 24.5x to about 18.1x, suggesting a lower valuation hurdle for the shares.

Have other thoughts on Viemed Healthcare?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystHighTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystHighTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystHighTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.